These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 33184416)
1. Possible contribution of sialic acid to the enhanced tumor targeting efficiency of nanoparticles engineered with doxorubicin. Lee SY; Nam S; Koo JS; Kim S; Yang M; Jeong DI; Hwang C; Park J; Cho HJ Sci Rep; 2020 Nov; 10(1):19738. PubMed ID: 33184416 [TBL] [Abstract][Full Text] [Related]
2. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles. Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911 [TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-Bound Hydroxyethyl Starch Conjugate Nanoparticles with pH/Redox Responsive Linkage for Enhancing Antitumor Therapy. Tan R; Tian D; Liu J; Wang C; Wan Y Int J Nanomedicine; 2021; 16():4527-4544. PubMed ID: 34276212 [TBL] [Abstract][Full Text] [Related]
4. PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy. Yang H; Shen W; Liu W; Chen L; Zhang P; Xiao C; Chen X Biomacromolecules; 2018 Nov; 19(11):4492-4503. PubMed ID: 30346147 [TBL] [Abstract][Full Text] [Related]
5. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study. Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748 [TBL] [Abstract][Full Text] [Related]
6. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine. Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129 [TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon. Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258 [TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-loaded poly (lactic-co-glycolic acid) nanoparticles coated with chitosan/alginate by layer by layer technology for antitumor applications. Chai F; Sun L; He X; Li J; Liu Y; Xiong F; Ge L; Webster TJ; Zheng C Int J Nanomedicine; 2017; 12():1791-1802. PubMed ID: 28424550 [TBL] [Abstract][Full Text] [Related]
9. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer. Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581 [TBL] [Abstract][Full Text] [Related]
10. Radiotherapy-induced enrichment of EGF-modified doxorubicin nanoparticles enhances the therapeutic outcome of lung cancer. Wang J; Zhang Y; Zhang G; Xiang L; Pang H; Xiong K; Lu Y; Li J; Dai J; Lin S; Fu S Drug Deliv; 2022 Dec; 29(1):588-599. PubMed ID: 35156493 [TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy. Zhang J; Tao W; Chen Y; Chang D; Wang T; Zhang X; Mei L; Zeng X; Huang L J Mater Sci Mater Med; 2015 Apr; 26(4):165. PubMed ID: 25791459 [TBL] [Abstract][Full Text] [Related]
12. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin. Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461 [TBL] [Abstract][Full Text] [Related]
13. Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity. Amini MA; Abbasi AZ; Cai P; Lip H; Gordijo CR; Li J; Chen B; Zhang L; Rauth AM; Wu XY J Natl Cancer Inst; 2019 Apr; 111(4):399-408. PubMed ID: 30239773 [TBL] [Abstract][Full Text] [Related]
14. Multifunctional Polyethylene Glycol (PEG)-Poly (Lactic-Co-Glycolic Acid) (PLGA)-Based Nanoparticles Loading Doxorubicin and Tetrahydrocurcumin for Combined Chemoradiotherapy of Glioma. Zhang X; Zhao L; Zhai G; Ji J; Liu A Med Sci Monit; 2019 Dec; 25():9737-9751. PubMed ID: 31856143 [TBL] [Abstract][Full Text] [Related]
15. Na Araste F; Abnous K; Hashemi M; Dehshahri A; Detampel P; Alibolandi M; Ramezani M Eur J Pharm Sci; 2020 Feb; 143():105207. PubMed ID: 31870814 [TBL] [Abstract][Full Text] [Related]
16. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer. Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487 [TBL] [Abstract][Full Text] [Related]
17. Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy. Bi D; Zhao L; Yu R; Li H; Guo Y; Wang X; Han M Drug Deliv; 2018 Nov; 25(1):564-575. PubMed ID: 29457518 [TBL] [Abstract][Full Text] [Related]
18. Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors. Kuo PH; Teng YH; Cin AL; Han W; Huang PW; Wang LH; Chou YT; Yang JL; Tseng YL; Kao M; Chang MD Drug Deliv; 2020 Dec; 27(1):542-555. PubMed ID: 32241176 [TBL] [Abstract][Full Text] [Related]
19. Self-assembled nanoparticles of reduction-sensitive poly (lactic-co-glycolic acid)-conjugated chondroitin sulfate A for doxorubicin delivery: preparation, characterization and evaluation. Wang XF; Ren J; He HQ; Liang L; Xie X; Li ZX; Zhao JG; Yu JM Pharm Dev Technol; 2019 Jul; 24(6):794-802. PubMed ID: 30907676 [TBL] [Abstract][Full Text] [Related]
20. PEGylated-PLGA Nanoparticles Coated with pH-Responsive Tannic Acid-Fe(III) Complexes for Reduced Premature Doxorubicin Release and Enhanced Targeting in Breast Cancer. Hu F; Zhang R; Guo W; Yan T; He X; Hu F; Ren F; Ma X; Lei J; Zheng W Mol Pharm; 2021 Jun; 18(6):2161-2173. PubMed ID: 32515968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]